newsfilter
← Latest News
GlobeNewswire·

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Teva and Prestige announce a license and supply agreement for the commercialization of Prestige's Tuznue®, a biosimilar to Herceptin® (trastuzumab) Tuznue® received European Commission (EC) marketing